1. Home
  2. TII vs PROF Comparison

TII vs PROF Comparison

Compare TII & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TII

Titan Mining Corporation

N/A

Current Price

$2.71

Market Cap

231.0M

Sector

N/A

ML Signal

N/A

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$6.71

Market Cap

238.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TII
PROF
Founded
2012
N/A
Country
Canada
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.0M
238.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TII
PROF
Price
$2.71
$6.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$6.38
$12.00
AVG Volume (30 Days)
177.5K
84.6K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.89
EPS
N/A
1.41
Revenue
N/A
$16,098,000.00
Revenue This Year
$4.20
$92.40
Revenue Next Year
$3.46
$64.10
P/E Ratio
$25.66
$4.93
Revenue Growth
N/A
50.73
52 Week Low
$2.09
$3.92
52 Week High
$5.65
$8.95

Technical Indicators

Market Signals
Indicator
TII
PROF
Relative Strength Index (RSI) 45.43 53.63
Support Level $2.48 $5.75
Resistance Level $3.05 $7.07
Average True Range (ATR) 0.15 0.39
MACD 0.02 0.00
Stochastic Oscillator 42.86 58.14

Price Performance

Historical Comparison
TII
PROF

About TII Titan Mining Corporation

Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: